Prime Stock Recommendation: An R&D focused company in the API space
N V Chandrachoodamani
Chandrachoodamani started his capital market career in mid 2000s with Equity Intelligence India and then worked with several capital market Intermediaries in various roles over the last 15 years. Most of his career experience has been in equity research and PMS. Most recently, he was with MOAT, a PMS firm. He is a graduate in mathematics, a post graduate in finance, and holds a CFP certification. LinkedIn|Twitter
All Posts »
More like this
Nifty IT Stocks Rally: A price bounce or a sector turnaround?
PrimeInvestor Research Team
August 4, 2026
Read More »
Technical outlook: Promise in Consumer Durables, the grind continues in Nifty50
B Krishnakumar
August 3, 2026
Read More »
4 thoughts on “Prime Stock Recommendation: An R&D focused company in the API space”
Hi Team,
Thanks for the insightful article. I do not have exposure currently to Pharma sector due to its volatile nature (US dependance). If i had to invest in 1, should it be Cipla or Glenmark? Which can give more price appreciation in next 1/2/3 years? If both can give an upside of 20% in 1 year i am happy to invest in both 🙂?
Abhinav
Welcome your query sir,
Glenmark life sciences is available at cheaper entry valuation, a criteria for better returns.
PE re-rating can happen if the Co delivers results consistently.
Meanwhile Cipla is a well established and successful Co.
If volatility is a concern, go for both.
Thank you
Hi,
One more question- GLS has risen 26% in last 1 year. Is it still a good entry point?
Welcome your query sir
The short answer is YES.
We have just initiated a buy on it. So long as a stock is in “buy” list, it is a buy.
Thank you
Comments are closed.